{"pmid":32375883,"pmcid":"PMC7200992","title":"Can computed tomography be a primary tool for COVID-19 detection? Evidence appraisal through meta-analysis.","text":["Can computed tomography be a primary tool for COVID-19 detection? Evidence appraisal through meta-analysis.","Crit Care","Huang, Edward Pei-Chuan","Sung, Chih-Wei","Chen, Chi-Hsin","Fan, Cheng-Yi","Lai, Pei-Chun","Huang, Yen-Ta","32375883"],"journal":"Crit Care","authors":["Huang, Edward Pei-Chuan","Sung, Chih-Wei","Chen, Chi-Hsin","Fan, Cheng-Yi","Lai, Pei-Chun","Huang, Yen-Ta"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32375883","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1186/s13054-020-02908-4","keywords":["covid-19","computed tomography","likelihood ratio","meta-analysis","sensitivity","specificity"],"link_comment_for":"32101510","topics":["Diagnosis"],"weight":1,"_version_":1666262687574654976,"score":9.490897,"similar":[{"pmid":32412790,"title":"Diagnostic Tools for Coronavirus Disease (COVID-19): Comparing CT and RT-PCR Viral Nucleic Acid Testing.","text":["Diagnostic Tools for Coronavirus Disease (COVID-19): Comparing CT and RT-PCR Viral Nucleic Acid Testing.","OBJECTIVE. Multiple studies suggest CT should be a primary diagnostic tool for coronavirus disease (COVID-19) because they reported sensitivities with CT far superior to that of reverse transcriptase polymerase chain reaction (RT-PCR) testing. This review aimed to assess these reports and found chest CT to have a clinical utility that is limited, particularly for patients who show no symptoms and patients who are screened early in disease progression. CONCLUSION. CT has limited sensitivity for COVID-19 and a lower specificity than RT-PCR testing, and it carries a risk of exposing providers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest CT should be considered a supplemental diagnostic tool, particularly for patients who show symptoms.","AJR Am J Roentgenol","Waller, Joseph V","Kaur, Parveer","Tucker, Amy","Lin, Keldon K","Diaz, Michael J","Henry, Travis S","Hope, Michael","32412790"],"abstract":["OBJECTIVE. Multiple studies suggest CT should be a primary diagnostic tool for coronavirus disease (COVID-19) because they reported sensitivities with CT far superior to that of reverse transcriptase polymerase chain reaction (RT-PCR) testing. This review aimed to assess these reports and found chest CT to have a clinical utility that is limited, particularly for patients who show no symptoms and patients who are screened early in disease progression. CONCLUSION. CT has limited sensitivity for COVID-19 and a lower specificity than RT-PCR testing, and it carries a risk of exposing providers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chest CT should be considered a supplemental diagnostic tool, particularly for patients who show symptoms."],"journal":"AJR Am J Roentgenol","authors":["Waller, Joseph V","Kaur, Parveer","Tucker, Amy","Lin, Keldon K","Diaz, Michael J","Henry, Travis S","Hope, Michael"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412790","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.2214/AJR.20.23418","keywords":["covid-19","rt-pcr","sars-cov-2","chest ct","coronavirus disease","sensitivity","severe acute respiratory syndrome coronavirus 2","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1666897318997131265,"score":100.826},{"pmid":32276333,"pmcid":"PMC7177594","title":"Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","text":["Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed.","Int J Mol Sci","Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung","32276333"],"abstract":["The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed."],"journal":"Int J Mol Sci","authors":["Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32276333","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/ijms21072574","keywords":["covid-19","covid-19-nsp2 assay","golaymetaminer","sars-cov-2","clinical evaluation","genome subtraction","nsp2","real-time rt-pcr","sensitivity","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491602337792,"score":87.60483},{"pmid":32298149,"title":"Chest CT and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date.","text":["Chest CT and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date.","OBJECTIVE. Coronavirus disease (COVID-19) is a global pandemic. Studies in the radiology literature have suggested that CT might be sufficiently sensitive and specific in diagnosing COVID-19 when used in lieu of a reverse transcription-polymerase chain reaction test; however, this suggestion runs counter to current society guidelines. The purpose of this article is to critically review some of the most frequently cited studies on the use of CT for detecting COVID-19. CONCLUSION. To date, the radiology literature on COVID-19 has consisted of limited retrospective studies that do not substantiate the use of CT as a diagnostic test for COVID-19.","AJR Am J Roentgenol","Raptis, Constantine A","Hammer, Mark M","Short, Ryan G","Shah, Amar","Bhalla, Sanjeev","Bierhals, Andrew J","Filev, Peter D","Hope, Michael D","Jeudy, Jean","Kligerman, Seth J","Henry, Travis S","32298149"],"abstract":["OBJECTIVE. Coronavirus disease (COVID-19) is a global pandemic. Studies in the radiology literature have suggested that CT might be sufficiently sensitive and specific in diagnosing COVID-19 when used in lieu of a reverse transcription-polymerase chain reaction test; however, this suggestion runs counter to current society guidelines. The purpose of this article is to critically review some of the most frequently cited studies on the use of CT for detecting COVID-19. CONCLUSION. To date, the radiology literature on COVID-19 has consisted of limited retrospective studies that do not substantiate the use of CT as a diagnostic test for COVID-19."],"journal":"AJR Am J Roentgenol","authors":["Raptis, Constantine A","Hammer, Mark M","Short, Ryan G","Shah, Amar","Bhalla, Sanjeev","Bierhals, Andrew J","Filev, Peter D","Hope, Michael D","Jeudy, Jean","Kligerman, Seth J","Henry, Travis S"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298149","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2214/AJR.20.23202","keywords":["covid-19","ct","coronavirus","infection","sensitivity","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493217144832,"score":87.60483},{"pmid":32434339,"title":"Testing for COVID-19: a few points to remember.","text":["Testing for COVID-19: a few points to remember.","Diagnostic approaches to COVID-19 include clinical history, PCR tests for the presence of SARS-CoV-2 virus and detection of antibodies. By combining these three approaches, the seroprevalence of anti-SARS-CoV-2 antibodies can be examined in healthcare teams. The aim of the study was to examine the seroprevalence of anti-SARS-CoV-2 antibodies in a population of healthcare professionals 6 - 8 weeks after the first COVID-19 case was detected in the Czech Republic. A total of 269 subjects were enrolled in the study (187 women, 82 men) with a median age of 45.9 years (21 - 71 years). We used a questionnaire to ascertain travel history and clinical signs of any respiratory tract infection. Blood samples were collected, and IgG levels were analysed in all samples. The level of IgA antibodies was analysed in those positive for IgG. PCR testing was performed in cases testing positive for presence of antibodies. The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 from Euroimmun (Germany) was used to analyse immunoglobulin levels. 17 % of the tested cohort reported symptoms compatible with COVID-19 and 35.8 % reported history of international travel. There were 5 subjects positive IgG cases (of 269; 1.85 %), and one IgA positive and IgG borderline positive subject (0.37 %). There was only one PCR positive subject. Anti SARS-CoV-2 antibodies were thus detected in 2.22% of participating health professionals. This article shows the pitfalls of the testing methods and highlights the necessity of using a correct testing algorithm, considering the character of the tested population and the expected low prevalence.","Cas Lek Cesk","Kratka, Zuzana","Luxova, Stepanka","Malickova, Karin","Furst, Tomas","Simkova, Halina","32434339"],"abstract":["Diagnostic approaches to COVID-19 include clinical history, PCR tests for the presence of SARS-CoV-2 virus and detection of antibodies. By combining these three approaches, the seroprevalence of anti-SARS-CoV-2 antibodies can be examined in healthcare teams. The aim of the study was to examine the seroprevalence of anti-SARS-CoV-2 antibodies in a population of healthcare professionals 6 - 8 weeks after the first COVID-19 case was detected in the Czech Republic. A total of 269 subjects were enrolled in the study (187 women, 82 men) with a median age of 45.9 years (21 - 71 years). We used a questionnaire to ascertain travel history and clinical signs of any respiratory tract infection. Blood samples were collected, and IgG levels were analysed in all samples. The level of IgA antibodies was analysed in those positive for IgG. PCR testing was performed in cases testing positive for presence of antibodies. The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 from Euroimmun (Germany) was used to analyse immunoglobulin levels. 17 % of the tested cohort reported symptoms compatible with COVID-19 and 35.8 % reported history of international travel. There were 5 subjects positive IgG cases (of 269; 1.85 %), and one IgA positive and IgG borderline positive subject (0.37 %). There was only one PCR positive subject. Anti SARS-CoV-2 antibodies were thus detected in 2.22% of participating health professionals. This article shows the pitfalls of the testing methods and highlights the necessity of using a correct testing algorithm, considering the character of the tested population and the expected low prevalence."],"journal":"Cas Lek Cesk","authors":["Kratka, Zuzana","Luxova, Stepanka","Malickova, Karin","Furst, Tomas","Simkova, Halina"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434339","source":"PubMed","week":"202021|May 18 - May 24","keywords":["covid-19","elisa","iga","igg","sars-cov-2","antibody","positive predictive value","rapid test","sensitivity","specificity"],"locations":["Czech Republic","Euroimmun","Germany"],"countries":["Germany","Czechia"],"countries_codes":["DEU|Germany","CZE|Czechia"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393693032449,"score":87.60483},{"pmid":32489929,"pmcid":"PMC7242306","title":"A systematic review of chest imaging findings in COVID-19.","text":["A systematic review of chest imaging findings in COVID-19.","Chest computed tomography (CT) is frequently used in diagnosing coronavirus disease 2019 (COVID-19) for detecting abnormal changes in the lungs and monitoring disease progression during the treatment process. Furthermore, CT imaging appearances are correlated with patients presenting with different clinical scenarios, such as early versus advanced stages, asymptomatic versus symptomatic patients, and severe versus nonsevere situations. However, its role as a screening and diagnostic tool in COVID-19 remains to be clarified. This article provides a systematic review and meta-analysis of the current literature on chest CT imaging findings with the aim of highlighting the contribution and judicious use of CT in the diagnosis of COVID-19. A search of PubMed/Medline, Web of Science, ScienceDirect, Google Scholar and Scopus was performed to identify studies reporting chest imaging findings in COVID-19. Chest imaging abnormalities associated with COVID-19 were extracted from the eligible studies and diagnostic value of CT in detecting these abnormal changes was compared between studies consisting of both COVID-19 and non-COVID-19 patients. A random-effects model was used to perform meta-analysis for calculation of pooled mean values and 95% confidence intervals (95% CI) of abnormal imaging findings. Fifty-five studies met the selection criteria and were included in the analysis. Pulmonary lesions more often involved bilateral lungs (78%, 95% CI: 45-100%) and were more likely to have a peripheral (65.35%, 95% CI: 25.93-100%) and peripheral plus central distribution (31.12%, 95% CI: 1.96-74.07%), but less likely to have a central distribution (3.57%, 95% CI: 0.99-9.80%). Ground glass opacities (GGO) (58.05%, 95% CI: 16.67-100%), consolidation (44.18%, 95% CI: 1.61-71.46%) and GGO plus consolidation (52.99%, 95% CI: 19.05-76.79%) were the most common findings reported in 94.5% (52/55) of the studies, followed by air bronchogram (42.50%, 95% CI: 7.78-80.39%), linear opacities (41.29%, 95% CI: 7.44-65.06%), crazy-paving pattern (23.57%, 95% CI: 3.13-91.67%) and interlobular septal thickening (22.91%, 95% CI: 0.90-80.49%). CT has low specificity in differentiating pneumonia-related lung changes due to significant overlap between COVID-19 and non-COVID-19 patients with no significant differences in most of the imaging findings between these two groups (P>0.05). Furthermore, normal CT (13.31%, 95% CI: 0.74-38.36%) was reported in 26 (47.3%) studies. Despite widespread use of CT in the diagnosis of COVID-19 patients based on the current literature, CT findings are not pathognomonic as it lacks specificity in differentiating imaging appearances caused by different types of pneumonia. Further, there is a relatively high percentage of normal CT scans. Use of CT as a first-line diagnostic or screening tool in COVID-19 is not recommended.","Quant Imaging Med Surg","Sun, Zhonghua","Zhang, Nan","Li, Yu","Xu, Xunhua","32489929"],"abstract":["Chest computed tomography (CT) is frequently used in diagnosing coronavirus disease 2019 (COVID-19) for detecting abnormal changes in the lungs and monitoring disease progression during the treatment process. Furthermore, CT imaging appearances are correlated with patients presenting with different clinical scenarios, such as early versus advanced stages, asymptomatic versus symptomatic patients, and severe versus nonsevere situations. However, its role as a screening and diagnostic tool in COVID-19 remains to be clarified. This article provides a systematic review and meta-analysis of the current literature on chest CT imaging findings with the aim of highlighting the contribution and judicious use of CT in the diagnosis of COVID-19. A search of PubMed/Medline, Web of Science, ScienceDirect, Google Scholar and Scopus was performed to identify studies reporting chest imaging findings in COVID-19. Chest imaging abnormalities associated with COVID-19 were extracted from the eligible studies and diagnostic value of CT in detecting these abnormal changes was compared between studies consisting of both COVID-19 and non-COVID-19 patients. A random-effects model was used to perform meta-analysis for calculation of pooled mean values and 95% confidence intervals (95% CI) of abnormal imaging findings. Fifty-five studies met the selection criteria and were included in the analysis. Pulmonary lesions more often involved bilateral lungs (78%, 95% CI: 45-100%) and were more likely to have a peripheral (65.35%, 95% CI: 25.93-100%) and peripheral plus central distribution (31.12%, 95% CI: 1.96-74.07%), but less likely to have a central distribution (3.57%, 95% CI: 0.99-9.80%). Ground glass opacities (GGO) (58.05%, 95% CI: 16.67-100%), consolidation (44.18%, 95% CI: 1.61-71.46%) and GGO plus consolidation (52.99%, 95% CI: 19.05-76.79%) were the most common findings reported in 94.5% (52/55) of the studies, followed by air bronchogram (42.50%, 95% CI: 7.78-80.39%), linear opacities (41.29%, 95% CI: 7.44-65.06%), crazy-paving pattern (23.57%, 95% CI: 3.13-91.67%) and interlobular septal thickening (22.91%, 95% CI: 0.90-80.49%). CT has low specificity in differentiating pneumonia-related lung changes due to significant overlap between COVID-19 and non-COVID-19 patients with no significant differences in most of the imaging findings between these two groups (P>0.05). Furthermore, normal CT (13.31%, 95% CI: 0.74-38.36%) was reported in 26 (47.3%) studies. Despite widespread use of CT in the diagnosis of COVID-19 patients based on the current literature, CT findings are not pathognomonic as it lacks specificity in differentiating imaging appearances caused by different types of pneumonia. Further, there is a relatively high percentage of normal CT scans. Use of CT as a first-line diagnostic or screening tool in COVID-19 is not recommended."],"journal":"Quant Imaging Med Surg","authors":["Sun, Zhonghua","Zhang, Nan","Li, Yu","Xu, Xunhua"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489929","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21037/qims-20-564","keywords":["covid-19","coronavirus infections","computed tomography (ct)","diagnosis","imaging","sensitivity","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1668623433532964864,"score":87.60483}]}